Failure to Rotate Insulin Injection Sites
Summary
The facility failed to ensure residents were free from significant medication errors by not rotating subcutaneous insulin administration sites for three of three sampled residents. The report states that the medication error involved preparation or administration of insulin that was not in accordance with the prescriber’s order, manufacturer’s specifications, and accepted professional standards. The deficiency was identified through interview and record review for residents receiving insulin therapy. One resident was admitted with diagnoses including type 2 diabetes mellitus and mild protein-calorie malnutrition. The resident’s orders included insulin with instructions to rotate injection sites, and the care plan also identified a potential for skin discoloration related to insulin injections with an intervention to rotate injection sites regularly. The location of administration record for March 2026 showed insulin was administered subcutaneously, and the Director of Staff Development stated there were multiple instances where licensed staff did not rotate the insulin administration sites. The DSD stated that rotating sites was important to prevent bruising and lipodystrophy and that administering insulin on sites of lipodystrophy could affect absorption and cause hypo- or hyperglycemia. A second resident with diagnoses including DM2 with diabetic neuropathy and morbid obesity had orders for NovoLog and facility-provided manufacturer information that directed injection site rotation within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. A third resident with diagnoses including DM2 and dementia had orders for Humulin R and insulin glargine that specifically directed rotation of injection sites. Review of the location of administration records showed repeated use of the same abdominal quadrant and repeated use of the left arm without rotation. The DSD and DON both stated that the insulin administration sites were not rotated, that insulin is a significant medication, and that failure to rotate sites was considered a medication error because it did not follow the physician’s order, manufacturer’s guidelines, and standards of practice.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.